Iris Isufi, MD

Assistant Professor of Medicine (Hematology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program


Transplantation Center, Yale-New Haven

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine)

  • Internal Medicine AB of Internal Medicine (2007)

  • Medical Oncology AB of Internal Medicine (2011)

Clinical Trials

Conditions Study Title
Hodgkin's Lymphoma E1411: Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma
Mycosis Fungoides MRG-106 injection in patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) sub-type
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic An Open-Label Study of a Novel JAK-inhibitor,INCB052793,Given to Patients With Advanced Malignancies
Non-Hodgkin's Lymphoma, Other Hematopoietic Phase 1b Study of CC-122, CC-223, CC-292 and Rituximab in DLBCL
Multiple Myeloma SHIVERING 2 Trial
Multiple Myeloma A Phase 1b Study of the Safety and Pharmacokinetics of MPDL3280A (Anti-PD-L1 Antibody)
Multiple Myeloma Ph III: Lenalidomide vs Observation in Pts with Asymptomatic High Risk Smoldering Myeloma
Leukemia, other, Lymphoid Leukemia Randomized Phase III: BR vs Ibrutinib +R vs Ibrutinib Alone in Untreated Older Pts with CLL
Lymphoid Leukemia Ibrutinib+Rituximab v. Fludarabine Phosphate, Cyclophosphamide, and Rituximab in untreated CLL
Ill-Defined Sites Multicenter Access and Distrubiton for Unlicensed CBUs for Transplantation
Melanoma, skin AdaptImmune Phase I/II Melanoma Trial
Non-Hodgkin's Lymphoma A Phase II Trial of PET-Directed Therapy for Limited Stage DLBCL (SWOG S1001)

Edit this profile

Contact Info

Iris Isufi, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 7

New Haven, CT 06510
View on map...
Mailing Address
333 Cedar Street FMP 130
PO Box 208032

New Haven, CT 06520-8032